Abstract Near-infrared (NIR) fluorescence imaging has the potential to improve sentinel lymph node (SLN) mapping in breast cancer. Indocyanine green (ICG) is currently the only clinically available fluorophore that can be used for SLN mapping. Preclinically, ICG adsorbed to human serum albumin (ICG:HSA) improves its performance as a lymphatic tracer in some anatomical sites. The benefit of ICG:HSA for SLN mapping of breast cancer has not yet been assessed in a clinical trial. We performed a doubleblind, randomized study to determine if ICG:HSA has advantages over ICG alone. The primary endpoint was the fluorescence brightness, defined as the signal-tobackground ratio (SBR), of identified SLNs. Clinical trial subjects were 18 consecutive breast cancer patients scheduled to undergo SLN biopsy. All patients received standard of care using 99m Technetium-nanocolloid and patent blue. Patients were randomly assigned to receive 1.6 ml of 500 lM ICG:HSA or ICG that was injected periareolarly directly after patent blue. The Mini-Fluorescence-Assisted Resection and Exploration (Mini-FLARE) imaging system was used for NIR fluorescence detection and quantitation. SLN mapping was successful in all patients. Patient, tumor, and treatment characteristics were equally distributed over the treatment groups. No significant difference was found in SBR between the ICG:HSA group and the ICG alone group (8.4 vs. 11.3, respectively, P = 0.18). In both groups, the average number of detected SLNs was 1.4 ± 0.5 SLNs per patient (P = 0.74). This study shows that there is no direct benefit of premixing ICG with HSA prior to injection for SLN mapping in breast cancer patients, thereby reducing the cost and complexity of the procedure. With these optimized parameters that eliminate the necessity of HSA, larger trials can now be performed to determine patient benefit.
Introduction
Sentinel lymph node (SLN) mapping is currently regarded as standard of care in staging of the axilla in breast cancer patients with clinically negative axillary lymph nodes [1] . In general, a combination of radioactive colloid and blue dye is used for SLN mapping. Using this combination, identification rates of 95 to 97% are achieved [2] [3] [4] [5] . The use of only one of these two detection methods results in significantly lower identification rates [2] [3] [4] [5] . Both detection methods possess certain disadvantages. Radioactive colloids require involvement of a nuclear medicine physician, can be difficult to localize with a handheld gamma probe, and the time-window for SLN identification is limited due to the short half-life (6 h) of 99m Technetium. Blue dyes cannot be seen through skin and fatty tissue, and permit only limited visualization of afferent lymphatic vessels and the SLN.
Optical imaging using the near-infrared (NIR) fluorescence lymphatic tracer indocyanine green (ICG) enables real-time transcutaneous and intraoperative visualization of lymphatic channels and SLNs [6] [7] [8] [9] [10] [11] [12] [13] . Therefore, NIR fluorescence imaging could provide an alternative for, or an addition to, conventional techniques used for SLN mapping. Recently, our group has demonstrated that NIR fluorescence performed equally well as the combination of radioactive colloid and blue dye in SLN mapping of breast cancer patients [14] .
ICG is currently the only clinically available NIR lymphatic tracer. However, due to its relatively low fluorescence brightness and its small hydrodynamic diameter, which permits flow through the SLN to higher tier nodes, it is not an optimal lymphatic tracer. Preclinical work has demonstrated that adsorption of ICG to human serum albumin (HSA, complex is ICG:HSA), by simply mixing it, increases the fluorescence intensity and the hydrodynamic diameter, thereby providing improved detection and better retention in the SLN in certain anatomical sites, such as the intestine [15] . Another parameter that must be considered when using ICG or ICG:HSA is the effect of fluorescence quenching, which results in a decrease in fluorescence intensity as the concentration of ICG (or ICG:HSA) is increased above 50 lM. The use of 50 lM ICG for SLN imaging, however, is suboptimal, because ICG will be diluted once taken up by the lymphatic system. To assess the magnitude of this in vivo dilution effect, our group has conducted a dose-finding study to demonstrate that the optimal concentration of ICG:HSA for NIR-based SLN mapping in breast cancer patients lies between 400 and 800 lM [14] .
A theoretical disadvantage of the use of ICG alone is poor retention of the lymphatic tracer in the SLN, which as a consequence results in fluorescent staining of higher tier nodes and background staining of the axilla. Although not compared directly, studies using ICG alone reported a higher average number of identified SLNs (range = 1.8-5.4; aggregate average = 3.4) [6] [7] [8] [9] [10] , than with the use of ICG:HSA (aggregate: 1.5) [11, 14] . However, comparison of these data is difficult because the concentration of ICG used was significantly higher (typically 6.4 mM) than in the trials using ICG:HSA (10-1000 lM).
Although we have obtained good results with the use of ICG:HSA for SLN mapping in breast cancer patients, the use of albumin adds cost and complexity to the procedure. Moreover, the use of human blood products, such as HSA, poses regulatory hurdles in certain countries, such as the United States. Therefore, the use of ICG alone would be favorable. After intravenous administration, ICG binds rapidly and completely to plasma proteins [16] . Lymph fluid has a similar protein constitution as serum, albeit in a lower concentration (20.6 g/l for lymph fluid versus 73.7 g/l for plasma) [17] . After intradermal or subcutaneous injection, ICG could theoretically bind to these proteins, eliminating the need for premixing ICG and HSA. We therefore hypothesized that ICG alone could render the same fluorescence intensity in SLNs as ICG:HSA, and tested this hypothesis in a double-blind randomized trial.
Methods
Preparation of indocyanine green adsorbed to human serum albumin Indocyanine green (25 mg vials) was purchased from Pulsion Medical Systems (Munich, Germany) and was resuspended in 10 cc of sterile water for injection to yield a 2.5 mg/ml (3.2 mM) stock solution. To obtain a 500 lM dilution, 7.8 mL of the 3.2 mM ICG solution was diluted in 50 cc vial of sterile water for injection or 50 cc vial of Cealb (20% human serum albumin, Sanquin, Amsterdam, The Netherlands) for the preparation of ICG alone or ICG:HSA, respectively. Prior to the addition of ICG, 7.8 ml was drawn from the 50 cc vials. In a previous study, we determined that the optimal dose of ICG:HSA lies between 400 and 800 lM [14] . A dose of 500 lM was chosen because it requires minimal manipulation of ICG and albumin volumes.
Intraoperative near-infrared imaging system (Mini-FLARE) SLN mapping was performed using the Mini-FluorescenceAssisted Resection and Exploration (Mini-FLARE) imageguided surgery system as described earlier [14] . Briefly, the system consists of two wavelengths isolated light sources: a ''white'' light source, generating 26,600 lx of 400-650 nm light, and a ''near-infrared'' light source, generating 7.7 mW/cm 2 of 760 nm light. Color video and NIR fluorescence images are simultaneously acquired and displayed in real-time using custom optics and software that separate the color video and NIR fluorescence images. A pseudocolored (lime green) merged image of the color video and NIR fluorescence images is also displayed. The imaging head is attached to a flexible gooseneck arm, which permits positioning of the imaging head at extreme angles virtually anywhere over the surgical field. For intraoperative use, the imaging head and imaging system pole stand are wrapped in a sterile shield and drape (Medical Technique Inc., Tucson, AZ).
Clinical trial
The double-blind, randomized, single-institution, noninferiority trial comparing ICG:HSA with ICG alone was approved by the Medical Ethics Committee of the Leiden University Medical Center and was performed in accordance with the ethical standards of the Helsinki Declaration of 1975. All patients planning to undergo a sentinel lymph node procedure whether for invasive breast cancer or for high-risk carcinoma in situ were eligible for participation in the study. Patients had clinically negative axillary nodes as assessed by palpation and ultrasonography. Exclusion criteria were pregnancy, lactation or an allergy to iodine, shellfish, or indocyanine green.
All patients gave informed consent and were anonymized. Patients were randomized by the Department of Clinical Pharmacy. Treatment allocation was performed by block randomization. Patients received the standard of care sentinel lymph node procedure. For our institution, this implies one periareolar injection of approximately 100 MBq 99m Technetium-nanocolloid (mean ± SD = 96.6 ± 14.7 MBq, no difference between treatment groups [P = 0.47]) the day before surgery. Before the start of the operation, one mL of patent blue V was injected. Directly after patent blue injection, the surgeon injected a total of 1.6 ml of 500 lM ICG:HSA or ICG alone. Both dyes were injected intradermally and periareolarly at four sites. Gentle pumping pressure was applied to the injection site for 1 min. After surgical scrub and sterile covering of the operation field, NIR fluorescence imaging was performed with the imaging head of the Mini-FLARE at *30 cm distance to the surgical field. Camera exposure times were between 5 and 200 ms. A SLN exhibiting a signal-tobackground ratio (SBR) C 1.1 in situ was considered positive by NIR fluorescence. Both the surgeon and the Mini-FLARE operator, who was responsible for analyzing the data, were blinded to the treatment allocation.
Routine histopathological frozen analysis of SLNs was performed during surgery. SLNs were fixed in formalin and embedded in paraffin for routine hematoxylin and eosin staining and immunohistopathological staining for AE1/ AE3 at three levels, with an interval of 150 to 250 lm, according to the Dutch guidelines for SLN analysis. Patients underwent an axillary lymph node dissection if the SLN was found to contain metastases. If isolated tumor cells were found (\0.2 mm), no axillary lymph node dissection was performed.
Power calculation and statistical analysis
A power calculation based on data from our previous study [14] revealed that 18 patients are needed to achieve 91% power to detect non-inferiority using a one-sided, twosample t test (a = 0.025) with a margin of equivalence of 5.0 while assuming no difference between the SBRs of ICG:HSA and ICG alone. For statistical analysis, SPSS statistical software package (Version 16.0, Chicago, IL) was used. Graphs were generated using GraphPad Prism Software (Version 5.01, La Jolla, CA). To compare the SBR and the number of SLNs identified between ICG:HSA and ICG alone, a one-sided, two-sample t-test was performed. P \ 0.05 was considered significant.
Results
Eighteen consecutive breast cancer patients undergoing standard of care SLN mapping were randomized to ICG:HSA or ICG alone for the NIR-based SLN imaging. Patient, tumor, and treatment characteristics were equally distributed over the treatment groups (Table 1) . Use of the Mini-FLARE during surgery did not interfere with the standard of care. Average time between lymphatic tracer injection and skin incision was 15.6 ± 2.2 min (Table 2) . In all patients (N = 18), NIR fluorescence imaging enabled visualization of one or more SLNs (Fig. 1) . In the ICG:HSA group (N = 8 subjects), a total of 11 SLNs were identified (average per patient = 1.4 ± 0.5); 9 (82%) were radioactive, 8 (73%) were blue and 11 (100%) were NIR fluorescent. In the ICG alone group (N = 10 subjects), a total of 14 SLNs were identified (average per patient = 1.4 ± 0.5); 14 (100%) were radioactive, 10 (71%) were blue and 14 (100%) were NIR fluorescent. The average number of SLNs identified was not significantly different between both groups (P = 0.74).
The primary endpoint of this study was the average brightness of the SLN in both groups, expressed in signalto-background ratio (SBR). The results are presented in Table 2 . The average SBR of ICG:HSA (8.4 ± 3.6) and ICG alone (11.3 ± 4.8) was not significantly different (P = 0.18). However, in the ICG alone group, the afferent lymphatics were significantly better visualized percutaneously compared to the ICG:HSA group (P = 0.004; Table 2 ; Fig. 1) .
In all patients, the NIR fluorescence signal in the SLN was detected earlier in the procedure before patent blue was visualized. Average time between skin incision and resection of the first SLN was 11.0 ± 4.1 min and was not different between both groups (t test, P = 0.74). No adverse reactions associated with the use of ICG, ICG:HSA, or Mini-FLARE occurred.
Discussion
The use of NIR fluorescence for SLN mapping has several advantages over conventional methods, such as better tissue penetration when compared to blue dyes, and lack of ionizing radiation and real-time visualization when compared to radiotracers. A number of clinical studies have been published on the use of NIR fluorescence in the SLN procedure in breast cancer, all of which use ICG, which is currently clinically available [6, 9, 11, 12, 14] . Preclinical studies indicated that adsorption of ICG to human serum albumin (HSA, complex is ICG:HSA), by simply mixing it, increases the fluorescence intensity and the hydrodynamic diameter, thereby providing improved detection and better retention in the SLN [15] . Our group has subsequently conducted a dose-finding study and demonstrated that the optimal concentration of ICG:HSA for NIR-based SLN mapping in breast cancer patients lies between 400 and 800 lM [14] . Indeed, above 800 lM ICG:HSA, the fluorescent intensity dropped due to quenching. Based on these results, a concentration of 500 lM ICG:HSA, which requires minimal manipulation of albumin volumes and uses only one vial of ICG, was chosen for further studies to identify whether premixing with albumin indeed increases the fluorescent intensity of the node in a clinical setting. In the current study, SLN mapping after ICG or ICG:HSA injection was successful in all patients. ICG showed a comparable or even slightly increased (though not significantly) brightness than ICG:HSA, while identifying an equal average number of SLNs. Although no macrometastases in the SLNs were observed in this study, our previous study showed that tumor-positive SLNs were also detected by NIR fluorescence, signifying ICG uptake [14] .
However, lymph node macrometastases continue to be a contraindication for SLN mapping and preoperative staging of the axilla remains pivotal to minimize false negatives.
The results of our study are discordant with preclinical work in intestine, which suggested an improvement in fluorescent brightness and retention in the SLN by premixing ICG with HSA [15] . Although this study was powered to determine non-inferiority in SBR of ICG alone when compared to ICG:HSA, it was not formally powered to assess the secondary endpoint, average number of SLNs identified. However, power analysis using data from our previous study [14] demonstrated that a difference of at least one additional SLN identified per patient could be detected with 90% power with the current sample size. The discrepancy between the current clinical results and these preclinical experiments could be caused by the increased distance that the injected dye has to travel, as the preclinical studies were performed in the bowel of healthy pigs [15] . Lymph fluid contains a high concentration of albumin, among other proteins; therefore, a longer traveling distance could aid ICG in adsorbing to albumin or other proteins, as it would after intravenous injection [18] , diminishing the need for premixing ICG with HSA. This observation implies that premixing might prove to be useful in other cancer types (such as colon cancer, for example), where ICG is less likely to completely adsorb to proteins before the SLN is reached. Therefore, the use of ICG:HSA or ICG alone should be tested for every anatomical site. Although the fluorescent brightness did not differ significantly between both groups, ICG alone showed significantly improved percutaneous visibility of lymphatic channels when compared to ICG:HSA (Fig. 1) . It has been shown that in plasma, ICG preferably binds to a 1 -lipoprotein and c-globulin, despite the higher concentration of albumin [19] . Previous experiments have shown a higher increase in quantum yield when ICG is mixed with serum, in comparison to HSA [15] . Therefore, the observed differences in visualization of lymphatics could likely be attributable to the protein constitution of lymph fluid. The high albumin content (20%) of ICG:HSA could also be a contributing factor, as the increased hydrodynamic diameter and higher viscosity could diminish ICG uptake in lymphatic channels. It should be noted that the anatomical variation (amount of tissue overlying the lymphatic channels) is also a major influencing factor and may be primarily responsible for the observed difference.
An optimal lymphatic tracer is non-toxic, has a high quantum yield (i.e., brightness), migrates quickly to the SLN, and does not migrate to higher tier nodes. If a tracer migrates to higher tier nodes, non-sentinel lymph nodes could incorrectly be identified as SLNs, causing more nodes than necessary to be resected. ICG is far from optimal; in aqueous solution the quantum yield is relatively low and due to its small hydrodynamic diameter, it can flow to higher tier nodes, as is the case with blue dyes. The synthesis and clinical introduction of an optimal probe will with NIR fluorescence imaging is demonstrated 28 min after injection of 1.6 ml of 500 lM ICG. Camera exposure times were 30 ms (top row) and 100 ms (bottom row). Scale bars represent 1 cm be the subject of future studies and will greatly help to confirm the clinical benefit of NIR fluorescence imaging in the SLN procedure [15, 20] .
In this study, NIR fluorescence after ICG injection could consistently be visualized before the blue dye could be observed, which is consistent with earlier findings [14] . Therefore, NIR fluorescence imaging has the potential to replace blue dyes in SLN mapping of breast cancer patients. Furthermore, as NIR fluorescence light penetrates relatively deep into tissue, it can potentially replace radiocolloids in SLN mapping in a selected group of patients, for example those with a low body mass index. A clinical trial on omitting blue dyes and using NIR fluorescence without the need for radiocolloids is currently ongoing (NTR2674).
In conclusion, this double-blind, randomized trial showed no advantage of ICG:HSA in comparison to ICG alone for the SLN procedure. To reduce the cost and complexity of the procedure, a dose of 500 lM ICG alone (1.6 ml) is recommended for NIR fluorescence SLN mapping in breast cancer patients. Therefore, this study has determined the optimal parameters that can be used to validate this technique in a larger series in order to investigate patient benefit.
